GSK484, a widely used specific PAD4 inhibitor in research, has been shown to ameliorate remote lung injury following AKI (9) and prevent cancer-associated kidney injury (151) by mitigating neutrophil infiltration and NET formation. The gene discussed is PADI4; the disease is acute kidney injury.